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amounted to 75.8%. 56.5% of pts had hypertension and 29.7%
were diabetic. Thirty-four percent of pts were diagnosed as obese
with additional 44.2% of the pts’ population being overweight.
The prevalence of current smokers was 17.5% in total study pop-
ulation and 15.8% in post myocardial infraction pts. Except ACEI
(70.6% vs. 69.5%) drugs such as ASA, LBA, statins were more
frequently applied in secondary prevention group when compared
with primary prevention pts (respectively 54.9% vs. 85.8%, 41.9
vs. 77.0%, 53.8 vs. 79.4%). Underweight pts received fewer rec-
ommendations concerning regular physical activity, dietary coun-
seling and weight loss when compared with obese pts (respectively
80.6% vs. 90.8%; 79.3% vs. 95.3%; 68.8% vs. 97.3%). CON-
CLUSIONS: The POLKARD-SPOK survey conﬁrmed a high
prevalence of modiﬁable risk factors and their inappropriate 
management, in patients with CVD or at high risk of fatal
atherothrombotic events, treated in primary care settings.
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OBJECTIVES: To summarize the diagnostic accuracy of coro-
nary pressure-based fractional ﬂow reserve (FFR) in patients
with suspected coronary artery disease. METHODS: A system-
atic search in literature databases (MEDLINE, EMBASE,
Cochrane and HTA-databases) up to 2005 was performed to
identify published studies comparing FFR with a functional ref-
erence standard and reporting test characteristics. As reference
standard SPECT, scintigraphy or combinations of several tests
(e.g. stress electrocardiography, stress echocardiography, angiog-
raphy) were accepted. We constructed diagnostic 2 × 2-tables
from diagnostic test characteristics (e.g., sensitivity, speciﬁcity)
and performed a diagnostic meta-analysis using the inverse 
variance approach. RESULTS: Thirteen articles were identiﬁed
matching the inclusion criteria. Four articles were excluded
because of multiple reporting of data. From the 9 studies
included, data for 717 observational units (i.e., patient or coro-
nary lesion) were extracted. Pooled sensitivity of FFR was 82%
(95%-CI: 77–86%), and speciﬁcity was 79% (74–83%). Diag-
nostic odds ratio was 16.5 (11.4–63.7). Excluding single studies
did not affect these results. Subgroup analyses showed severity
of disease reﬂected by the number of affected coronary vessels
as an inﬂuential factor on test sensitivity (single-vessel-disease:
95% [87–99%] vs. 78% [73–83%] in multi-vessel-disease).
Choice of reference standard also inﬂuenced pooled sensitivity.
Studies using SPECT as reference standard showed a lower 
sensitivity than studies using other reference standards (78%
[73–83%] vs. 95% [87–99%]). Subgroups of studies with multi-
vessel-disease patients and studies using SPECT as reference stan-
dard tended to be of newer publication date. CONCLUSIONS:
FFR is a functional test with sufﬁciently high sensitivity and
speciﬁcity for the detection of hemodynamic relevant coronary
stenoses. Time trends in the data affecting the overall estimate
of pooled sensitivity can not be excluded, but are unlikely to rel-
evantly inﬂuence the result.
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OBJECTIVE: Drug-eluting stents (DES) have become the prin-
cipal coronary artery revascularization modality in the US; yet
little is known about their long-term clinical outcomes versus
bare-metal stents (BMS). We examined 2-year clinical event rates
for BMS vs. DES in a practice-based population and compared
results for patients with single- as well as multi-vessel coronary
artery disease (CAD). METHODS: The study population
includes Duke University Medical Center patients undergoing
revascularization with BMS or DES between January 1, 2000
and May 31, 2005, with follow-up through August 17, 2006.
Study outcomes examined are death, non-fatal myocardial
infarction (MI), and target vessel revascularization (TVR), and
their composites. RESULTS: We examined the data of 3678 BMS
and 1689 DES patients. DES vs. BMS patients had more multi-
vessel CAD (42.6% vs. 36.6%). At two years follow-up, DES vs.
BMS patients had lower rates of mortality (7.8% vs. 8.6%), non-
fatal MI (3.3% vs. 5.0%), and TVR (6.0% vs. 14.2%). This dif-
ference in DES vs. BMS TVR rate was observed in patients with
1- (5.5% vs. 13.0%), 2- (6.7% vs. 15.7%), and 3-vessel CAD
(7.0% vs. 18.8%). After adjustment for differences in baseline
characteristics using Cox proportional hazards modeling, DES
vs. BMS use was associated with no difference in mortality; but
with signiﬁcant reductions in the composites of death or MI (HR
= 0.81, 95% CI = 0.67, 0.98) and death, MI, or TVR (HR =
0.55, 95% CI = 0.47, 0.64). Event reduction in the adjusted
models was not limited to 1-, 2-, or 3-vessel CAD patients. CON-
CLUSIONS: The use of drug-eluting vs. bare-metal stents is 
associated with signiﬁcant improvements in long-term clinical
outcomes for patients with single- and multi-vessel coronary
artery disease.
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OBJECTIVES: Scottish Intercollegiate Guidelines Network
(SIGN) guidelines advise that at risk patients should be treated
to a total cholesterol (TC) target of <5 mmol/L. Recent Joint
British Societies Guidelines (JBS2, 2005) recommend patients be
treated to a lower TC target of <4 mmol/L. An audit was con-
ducted to determine the effect of the new guidelines on the 
proportion of patients achieving target cholesterol levels with
rosuvastatin. METHODS: General Practice records were
searched to identify patients who had been prescribed rosuvas-
tatin 10 mg and the following data recorded: previous statin
therapy, last cholesterol result on that statin and ﬁrst cholesterol
test on rosuvastatin 10 mg. RESULTS: A total of 508 patients
who had previously been prescribed rosuvastatin 10 mg were
identiﬁed. Of these 376 had both a pre- and post-rosuvastatin
treatment total cholesterol test. The majority of patients were
statin-naive (n = 253), the others had previously been prescribed
atorvastatin, mean dose 14 mg (n = 102), simvastatin mean dose
19 mg (n = 22) or pravastatin mean dose 15 mg (n = 2). Prior to
treatment with rosuvastatin 13% (49/376) had a TC <5 mmol/L,
increasing to 81% (303/376) after treatment with rosuvastatin
10 mg. In previously statin naïve patients 82% (208/253)
achieved TC <5 mmol/L on rosuvastatin compared to 77%
(95/123) in patients who had previously been treated with
another statin. On average patients experienced a 1.6 mmol/L
(27%) reduction in TC (32% in statin naïve, 16% where statin
changed). Improvements were also seen against JBS2 targets;
patients with TC <4 mmol/L improved from 3% (11/376) prior
to rosuvastatin to 35% (131/376) on rosuvastatin 10 mg (37%
in statin naïve, 30% where statin changed). CONCLUSIONS:
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Rosuvastatin 10 mg was effective in the reduction of TC in a
Scottish General Practice. The majority of patients were able to
achieve SIGN targets and many patients also achieved the lower
JBS2 targets.
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OBJECTIVES: The All Wales Medicines Strategy Group
(AWMSG) recommends that at risk patients should be treated to
a total cholesterol (TC) target of <5 mmol/L and low density
lipoprotein-cholesterol (LDL-C) <3 mmol/L. Recent Joint British
Societies Guidelines (JBS2, 2005) advise patients be treated to
TC <4 mmol/L and LDL-C <2 mmol/L. An audit was conducted
to determine the effect of the new guidelines on the proportion
of patients achieving target cholesterol levels with rosuvastatin.
METHODS: General Practice records were searched to identify
patients who had been prescribed rosuvastatin 10 mg and the fol-
lowing data recorded: previous statin therapy, last cholesterol
result on that statin and ﬁrst cholesterol test on rosuvastatin.
RESULTS: A total of 337 patients who had been prescribed
rosuvastatin were identiﬁed. Of these 273 patients prescribed
rosuvastatin 10 mg had both a pre- and post-rosuvastatin treat-
ment TC result, 33 had LDL-C results. The majority of patients
were statin-naive (195), others had previously been prescribed
atorvastatin mean dose 18 mg (n = 45), simvastatin mean dose
20 mg (n = 29) or pravastatin mean dose 23 mg (n = 4). Prior to
treatment with rosuvastatin, 11% (29/273) had a TC <5 mmol/L,
increasing to 79% (215/273) after treatment with rosuvastatin
10 mg. On average patients experienced a 1.6 mmol/L (26%)
reduction in TC. The proportion of patients with LDL-C 
<3 mmol/L improved from 12% (4/33) to 94% (31/33) on rosu-
vastatin. On average patients experienced a 1.6 mmol/L (42%)
reduction in LDL-C. Improvements were also seen against JBS2
targets; patients with TC <4 mmol/L improved from 0% prior 
to rosuvastatin to 32% on rosuvastatin 10 mg and similarly
patients with LDL-C <2 mmol/L improved from 0% to 39%.
CONCLUSIONS: Rosuvastatin 10 mg wass effective in the
reduction of TC and LDL-C in a Welsh general practice. The
majority of patients were able to achieve AWMSG targets and
many patients also achieve the recommended lower JBS2 targets.
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OBJECTIVES: To compare the effectiveness of statins in a real
world setting as measured by percentage low density lipoprotein
cholesterol (LDL-C) reduction and percentage total cholesterol
(TC) reduction in patients newly initiated on statin therapy.
METHODS: For this retrospective cohort study, patients newly
initiated on common start doses of statin therapies (rosuvastatin
10 mg, simvastatin 10/20 mg, pravastatin 20/40 mg and atorvas-
tatin 10/20 mg) between January 1, 2003 and August 31, 2005
were identiﬁed from the UK DIN-LINK database. Patients with
no dyslipidemic therapy in the 12 months preceding their initial
statin prescription and an LDL-C or TC measurement less than
6 months before and at least 1 month after initiating statin
therapy were included in the study. Adjusted percent LDL-C
reductions and percent TC reductions were compared using
linear regression techniques. RESULTS: A total of 2151 patients
with complete LDL-C data were identiﬁed. Rosuvastatin (n =
159), atorvastatin (n = 836), simvastatin (n = 1107) and pravas-
tatin (n = 49) groups were similar with respect to mean age (64.5,
64.4, 65.1 and 65.1 years respectively) and baseline LDL-C levels
(4.4, 4.3, 4.3 and 4.0 mmol/L respectively). After adjusting for
age, gender, baseline LDL-C, therapy duration and 2003 Euro-
pean guideline risk factors, patients initiated on rosuvastatin
achieved a signiﬁcantly greater percentage LDL-C reduction
(44.8%; 95% conﬁdence interval 42.1%–47.4%) than patients
initiated on atorvastatin (40.4%; 39.2%–41.5%), simvastatin
(36.5%; 35.5%–37.5%) or pravastatin (29.9%; 25.1%–34.5%):
all p < 0.01. Similarly, in patients where complete TC data was
available (n = 7070), patients initiated on rosuvastatin (n = 475)
had a signiﬁcantly greater adjusted percentage TC reduction
(31.3%; 30.1%–32.5%) than patients initiated on atorvastatin
(n = 2662; 28.2%; 27.7%–28.7%), simvastatin (n = 3665;
25.3%; 24.9%–25.7%) or pravastatin (n = 268; 20.7%;
19.1%–22.3%): all p < 0.0001. CONCLUSIONS: In patients
newly initiated on usual start doses of statins in routine practice,
rosuvastatin was more effective in lowering both LDL-C and TC
than atorvastatin, simvastatin and pravastatin.
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OBJECTIVE: Low adherence to antihypertensive drug (AHT)
treatment may limit patient’s beneﬁts in terms of a reduction of
cardiovascular and cerebrovascular disease. This study investi-
gated the relationship between persistence with antihypertensive
drugs and risk of myocardial infarction (MI) or stroke in daily
practice. METHODS: From the PHARMO record linkage
system comprising, among other medical information, the med-
ication histories and hospital discharge diagnoses of >2 million
inhabitants in The Netherlands, new users of AHT were identi-
ﬁed between 1993–2002. Persistence with AHT was determined
by summing the number of days of continuous treatment (gaps
between dispensings <60 days). Persistent patients remained on
AHT for 24 months. The outcome of interest was the ﬁrst hos-
pital admission for MI or stroke occurring two or more years
after initiation of AHT therapy. Patients were classiﬁed at high,
intermediate or low cardiovascular risk based on other cardio-
vascular drug use and hospitalizations during the ﬁrst two years
of follow-up. RESULTS: The study included 98,485 patients of
whom 16% were at high cardiovascular risk. About 50% (n =
48,548) of all patients were persistent with AHT for two years.
Multivariate analyses showed that persistent users of AHT had
a statistically signiﬁcant lower risk for MI/stroke compared to
non-persistent users (RRadj = 0.88; 95%CI: 0.82–0.94). The
association was stronger in the low/intermediate risk group
(RRadj = 0.85; 95%CI: 0.79–0.92) than in the high risk group
(RRadj = 0.95; 95%CI: 0.83–1.09). CONCLUSION: Non-
persistent use of AHT in daily practice leads to increased risk of
hospitalizations for MI or stroke.
